Trial Profile
The effect of sildenafil (REVatio), a PDE-5 inhibitor, on post cardiac surgery acute kidney injury: a randomised, placebo-controlled phase IIb clinical trial: The REVAKI-2 Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2023
Price :
$35
*
At a glance
- Drugs Sildenafil (Primary)
- Indications Acute kidney injury
- Focus Pharmacodynamics
- Acronyms REVAKI 2
- 31 Mar 2020 Primary endpoint has been met. (serum creatinine concentration)
- 31 Mar 2020 Primary endpoint has not been met. (serum creatinine concentration)
- 31 Mar 2020 Primary endpoint has been met. (serum creatinine concentration)